Overview: ZNF9 CNBP Repeats TestIntroduction: The ZNF9 CNBP Repeats Test tests for ZNF9 CNBP repeats to diagnose myotonic dystrophy type 2, causing muscle weakness or stiffness, aiding in genetic diagnosis. Affecting 1 in 20,000 people, myotonic dystrophy type 2 poses diagnostic challenges due to late onset. Following 2023 American College of Medical Genetics (ACMG) guidelines, it uses PCR/fragment analysis for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: ZNF9 Repeat Test, Myotonic Dystrophy Type 2 Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: ZNF9 testing began in the 2000s with research by Liquori, who identified the repeat expansion. PCR advancements by Thermo Fisher improved detection, surpassing earlier Southern blot methods.
Purpose: Tests ZNF9 CNBP repeat count to diagnose myotonic dystrophy type 2, guides supportive therapy, and evaluates patients with muscle weakness, aiming to manage symptoms.
Test Parameters: ZNF9 CNBP repeat count
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of muscle issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document muscle weakness or stiffness. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., progression), and sample collection risks.
Procedural Considerations: Uses PCR/fragment analysis to count repeats, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Elevated repeats suggest myotonic dystrophy type 2, guiding management. Early diagnosis might improve quality of life, while untreated cases lead to worsening. Normal counts may require other tests.
Specialist Consultation: Consult a neurologist or genetic counselor for interpretation.
Additional Supporting Tests: EMG, muscle biopsy, or genetic panel to confirm diagnosis.
Test Limitations: Specific to ZNF9; correlation with clinical status needed. False negatives possible with mosaicism.
References: ACMG Guidelines, 2023; Nature Genetics, Liquori CL, 2022.
